The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression

Clinical Cancer Research

Volumn 17, Issue 20, 2011, Pages 6373-6380

  Hedley, Benjamin D ^a   Allan, Alison L ^b,c   Xenocostas, Anargyros ^a,b,c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN RECEPTOR; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; TRASTUZUMAB;

ANEMIA; APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESISTANCE; DRUG TARGETING; ERYTHROCYTE; ERYTHROID PRECURSOR CELL; GROWTH; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANEMIA; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG INTERACTIONS; ERYTHROPOIETIN; HEMATINICS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 80054105158     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2577     Document Type: Review

References (74)

1. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999;14 Suppl 2:22-8. (Pubitemid 29154936)
2. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008;141:14-31. (Pubitemid 351347536)
3. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001;18:243-59. (Pubitemid 34044509)
4. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-605. (Pubitemid 46179448)
5. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24. (Pubitemid 351397066)
6. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-47.
7. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42.
8. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71.
9. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42. (Pubitemid 38886736)
10. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004;101:14907-12. (Pubitemid 39410773)
11. Um M, Gross AW, Lodish HFA. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007;19:634-45. (Pubitemid 46107815)
12. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:e647-56.
13. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000;19:2496-504. (Pubitemid 30339205)
14. Komatsu N, Adamson JW, Yamamoto K, Altschuler D, Torti M, Marzocchini R, et al. Erythropoietin rapidly induces tyrosine phosphorylation in the human erythropoietin-dependent cell line, UT-7. Blood 1992;80:53-9.
15. Chen C, Sytkowski AJ. Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc. J Biol Chem 2001;276:38518-26.
16. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22:2755-66.
17. Boudot C, Petitfrère E, Kadri Z, Chretien S, Mayeux P, Haye B, et al. Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2). J Biol Chem 1999;274:33966-72. (Pubitemid 129511725)
18. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004;23:8017-23. (Pubitemid 39468859)
19. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 2010;16:3811-8.
20. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol 2010;28:3366-79.
21. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15:146-55. (Pubitemid 40332537)
22. Dunlop EA, Maxwell AP, Lappin TR. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells 2007;25:380-4. (Pubitemid 46232792)
23. Solar P, Feldman L, Jeong JY, Busingye JR, Sytkowski AJ. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer 2008;122:281-8. (Pubitemid 350234713)
24. Solár P, Koval J, Mikes J, Kleban J, Solárová Z, Lazúr J, et al. Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells. Mol Cancer Ther 2008;7:2263-71.
25. Jacobs-Helber SM, Roh KH, Bailey D, Dessypris EN, Ryan JJ, Chen J, et al. Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood 2003; 101:524-31. (Pubitemid 36077573)
26. Wen TC, Sadamoto Y, Tanaka J, Zhu PX, Nakata K, Ma YJ, et al. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 2002;67:795-803. (Pubitemid 34226292)
27. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-7. (Pubitemid 32772276)
28. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab 2003;23:320-30. (Pubitemid 36307576)
29. Chong ZZ, Lin SH, Kang JQ, Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res 2003;71:659-69. (Pubitemid 36255350)
30. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-9. (Pubitemid 35424751)
31. Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007;9:1122-9. (Pubitemid 350255350)
32. Carvalho G, Lefaucheur C, Cherbonnier C, Métivier D, Chapel A, Pallardy M, et al. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 2005;24:737-45. (Pubitemid 40216083)
33. Studer L, Csete M, Lee SH, Kabbani N, Walikonis J, Wold B, et al. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 2000;20:7377-83.
34. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001;21:9733-43. (Pubitemid 34184059)
35. Ingley E, Chappell D, Poon SY, Sarna MK, Beaumont JG, Williams JH, et al. Thyroid hormone receptor-interacting protein 1 modulates cytokine and nuclear hormone signaling in erythroid cells. J Biol Chem 2001;276:43428-34.
36. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000;97:10526-31.
37. Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044-9. (Pubitemid 32249895)
38. Matsushita H, Johnston MV, Lange MS, Wilson MA. Protective effect of erythropoietin in neonatal hypoxic ischemia in mice. Neuroreport 2003;14:1757-61. (Pubitemid 37323768)
39. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971-5. (Pubitemid 37152934)
40. Xenocostas A, Cheung WK, Farrell F, Zakszewski C, Kelley M, Lutynski A, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005;61:189-95. (Pubitemid 40768551)
41. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxiainducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996;271:32253-9. (Pubitemid 26422262)
42. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987-92.
43. Wang GL, Jiang BH, Semenza GL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem Biophys Res Commun 1995;216:669-75.
44. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 1998;17:6573-86. (Pubitemid 28521792)
45. Elliott S, Busse L, Spahr C, Sinclair AM. Anti-EpoR antibodies detect a 59-kDa EpoR protein. Blood 2006;108:1107-9.
46. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-5. (Pubitemid 43289368)
47. Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010;115:4254-63.
48. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010;18:423-35.
49. Untch M, Fasching PA, Bauerfeind I, Conrad U, Camara O, Fett W, et al. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel {±} darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. J Clin Oncol 2008;26(15S):517.
50. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-15.
51. Newland AM, Black CD. Tumor progression associated with erythropoiesis- stimulating agents. Ann Pharmacother 2008;42:1865-70.
52. Dicato M, Plawny L. Erythropoietin in cancer patients: pros and cons. Curr Opin Oncol 2010;22:307-11.
53. Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer 2009;101:1961-71.
54. Leyland-Jones BBEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
55. Moebus V, Lueck H, Thomssen C, Harbeck N, Nitz U, Kreienberg R, et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 2007;25(18S):569.
56. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; 3 (Suppl 3):S116-20.
57. Pronzato P, Cortesi E, van der Rijt C, Moreno-Nogueira JA, Raimundo D, Ostler P, et al. Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): Results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group). Ann Oncol 2002;13:1.
58. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee. AmericanSociety of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010;116:4045-59.
59. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007;110:477-88. (Pubitemid 47106135)
60. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5. (Pubitemid 32694960)
61. Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004;23:981-90. (Pubitemid 38250944)
62. Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004;3:1525-32. (Pubitemid 40136707)
63. Hedley BD, Allan AL, Chu JE, Beausoleil M, Boasie A, Ormond DG, et al. Recombinant human erythropoietin (rHuEPO) in combination with chemotherapy increases breast cancer metastasis in preclinical mouse. Joint MRS-AACR conference (Meeting Abstracts) 2010:52.
64. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008;10:932-9.
65. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol 1999;73:280-4. (Pubitemid 29215744)
66. Stüben G, Thews O, Pöttgen C, Knühmann K, Vaupel P, Stuschke M. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-50. (Pubitemid 32453676)
67. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemiainduced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-61. (Pubitemid 34292556)
68. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25-41.
69. Janmaat ML, Heerkens JL, de Bruin AM, Klous A, de Waard V, de Vries CJ. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010;115:1453-60.
70. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36. (Pubitemid 29181195)
71. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-70. (Pubitemid 46582040)
72. Malik G, Knowles LM, Dhir R, Xu S, Yang S, Ruoslahti E, et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res 2010;70:4327-34.
73. Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-86.
74. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004;27:185-90. (Pubitemid 38221077)